Immunoglobulin light chain amyloidosis (AL)

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Light chain amyloidosis needs to be considered in the differential diagnosis of patients with nondiabetic nephrotic range proteinuria, unexplained fatigue or heart failure with preserved ejection fraction, a progressive peripheral neuropathy associated with a monoclonal protein, or atypical multiple myeloma. Screening involves serum and urine immunofixation and an immunoglobulin free light chain assay. Most patients can have the diagnosis established via biopsy of the bone marrow and subcutaneous fat. Visceral organ biopsy is rarely needed. The prognosis is determined by the DFLC, the levels of cardiac biomarkers, troponin and BNP. Therapy includes high-dose chemotherapy; and for patients ineligible for high-dose chemotherapy, bortezomib appears to be the single most active agent. Combinations of bortezomib and the inclusion of monoclonal antibodies are the subject of further studies.

Original languageEnglish (US)
Title of host publicationNeoplastic Diseases of the Blood
PublisherSpringer International Publishing
Pages651-672
Number of pages22
ISBN (Electronic)9783319642635
ISBN (Print)9783319642628
DOIs
StatePublished - Jan 1 2018

Fingerprint

Immunoglobulin Light Chains
Amyloidosis
Biopsy
Drug Therapy
Troponin
Subcutaneous Fat
Peripheral Nervous System Diseases
Multiple Myeloma
Proteinuria
Fatigue
Differential Diagnosis
Heart Failure
Biomarkers
Bone Marrow
Monoclonal Antibodies
Urine
Light
Serum
Proteins
Bortezomib

Keywords

  • Amyloidosis
  • Bortezomib
  • Cardiac biomarkers
  • Congo red
  • Fat aspiration
  • Heart failure
  • Immunoglobulin light chain
  • Lenalidomide
  • Melphalan
  • Multiple myeloma
  • Nephrotic syndrome
  • Peripheral neuropathy
  • Stem cell transplant
  • Thalidomide

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gertz, M., Buadi, F. K., Sher, T., & Dispenzieri, A. (2018). Immunoglobulin light chain amyloidosis (AL). In Neoplastic Diseases of the Blood (pp. 651-672). Springer International Publishing. https://doi.org/10.1007/978-3-319-64263-5_36

Immunoglobulin light chain amyloidosis (AL). / Gertz, Morie; Buadi, Francis K.; Sher, Taimur; Dispenzieri, Angela.

Neoplastic Diseases of the Blood. Springer International Publishing, 2018. p. 651-672.

Research output: Chapter in Book/Report/Conference proceedingChapter

Gertz, M, Buadi, FK, Sher, T & Dispenzieri, A 2018, Immunoglobulin light chain amyloidosis (AL). in Neoplastic Diseases of the Blood. Springer International Publishing, pp. 651-672. https://doi.org/10.1007/978-3-319-64263-5_36
Gertz M, Buadi FK, Sher T, Dispenzieri A. Immunoglobulin light chain amyloidosis (AL). In Neoplastic Diseases of the Blood. Springer International Publishing. 2018. p. 651-672 https://doi.org/10.1007/978-3-319-64263-5_36
Gertz, Morie ; Buadi, Francis K. ; Sher, Taimur ; Dispenzieri, Angela. / Immunoglobulin light chain amyloidosis (AL). Neoplastic Diseases of the Blood. Springer International Publishing, 2018. pp. 651-672
@inbook{fe1d1723ea684663a36d9d932e92c640,
title = "Immunoglobulin light chain amyloidosis (AL)",
abstract = "Light chain amyloidosis needs to be considered in the differential diagnosis of patients with nondiabetic nephrotic range proteinuria, unexplained fatigue or heart failure with preserved ejection fraction, a progressive peripheral neuropathy associated with a monoclonal protein, or atypical multiple myeloma. Screening involves serum and urine immunofixation and an immunoglobulin free light chain assay. Most patients can have the diagnosis established via biopsy of the bone marrow and subcutaneous fat. Visceral organ biopsy is rarely needed. The prognosis is determined by the DFLC, the levels of cardiac biomarkers, troponin and BNP. Therapy includes high-dose chemotherapy; and for patients ineligible for high-dose chemotherapy, bortezomib appears to be the single most active agent. Combinations of bortezomib and the inclusion of monoclonal antibodies are the subject of further studies.",
keywords = "Amyloidosis, Bortezomib, Cardiac biomarkers, Congo red, Fat aspiration, Heart failure, Immunoglobulin light chain, Lenalidomide, Melphalan, Multiple myeloma, Nephrotic syndrome, Peripheral neuropathy, Stem cell transplant, Thalidomide",
author = "Morie Gertz and Buadi, {Francis K.} and Taimur Sher and Angela Dispenzieri",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/978-3-319-64263-5_36",
language = "English (US)",
isbn = "9783319642628",
pages = "651--672",
booktitle = "Neoplastic Diseases of the Blood",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Immunoglobulin light chain amyloidosis (AL)

AU - Gertz, Morie

AU - Buadi, Francis K.

AU - Sher, Taimur

AU - Dispenzieri, Angela

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Light chain amyloidosis needs to be considered in the differential diagnosis of patients with nondiabetic nephrotic range proteinuria, unexplained fatigue or heart failure with preserved ejection fraction, a progressive peripheral neuropathy associated with a monoclonal protein, or atypical multiple myeloma. Screening involves serum and urine immunofixation and an immunoglobulin free light chain assay. Most patients can have the diagnosis established via biopsy of the bone marrow and subcutaneous fat. Visceral organ biopsy is rarely needed. The prognosis is determined by the DFLC, the levels of cardiac biomarkers, troponin and BNP. Therapy includes high-dose chemotherapy; and for patients ineligible for high-dose chemotherapy, bortezomib appears to be the single most active agent. Combinations of bortezomib and the inclusion of monoclonal antibodies are the subject of further studies.

AB - Light chain amyloidosis needs to be considered in the differential diagnosis of patients with nondiabetic nephrotic range proteinuria, unexplained fatigue or heart failure with preserved ejection fraction, a progressive peripheral neuropathy associated with a monoclonal protein, or atypical multiple myeloma. Screening involves serum and urine immunofixation and an immunoglobulin free light chain assay. Most patients can have the diagnosis established via biopsy of the bone marrow and subcutaneous fat. Visceral organ biopsy is rarely needed. The prognosis is determined by the DFLC, the levels of cardiac biomarkers, troponin and BNP. Therapy includes high-dose chemotherapy; and for patients ineligible for high-dose chemotherapy, bortezomib appears to be the single most active agent. Combinations of bortezomib and the inclusion of monoclonal antibodies are the subject of further studies.

KW - Amyloidosis

KW - Bortezomib

KW - Cardiac biomarkers

KW - Congo red

KW - Fat aspiration

KW - Heart failure

KW - Immunoglobulin light chain

KW - Lenalidomide

KW - Melphalan

KW - Multiple myeloma

KW - Nephrotic syndrome

KW - Peripheral neuropathy

KW - Stem cell transplant

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=85047034648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047034648&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-64263-5_36

DO - 10.1007/978-3-319-64263-5_36

M3 - Chapter

SN - 9783319642628

SP - 651

EP - 672

BT - Neoplastic Diseases of the Blood

PB - Springer International Publishing

ER -